CA2119571A1 - Retinoids and their use in treating skin diseases and leukemia - Google Patents
Retinoids and their use in treating skin diseases and leukemiaInfo
- Publication number
- CA2119571A1 CA2119571A1 CA002119571A CA2119571A CA2119571A1 CA 2119571 A1 CA2119571 A1 CA 2119571A1 CA 002119571 A CA002119571 A CA 002119571A CA 2119571 A CA2119571 A CA 2119571A CA 2119571 A1 CA2119571 A1 CA 2119571A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- formula
- acid
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/80—Phthalic acid esters
- C07C69/82—Terephthalic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/86—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compounds of formula (I) or (II) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1 is C1 to C8 alkyl and Q is selected from (a), (b), (c), (d), (e) and (f), wherein Y
is selected from (III), (IV), (V), (VI), (VII), (VIII), (IX) and (X) and Z is selected from groups of formula (XI), with the pharmaceutically acceptable salts and prodrugs of the aforesaid formula I or II final products being derived from the hereinbefore described Y and Z acid groups. These compounds are useful in treating aging skin, and also skin conditions such as psoriasis, acne and related disorder of keratinization and epithelial differentiation, as well as skin tumors.
is selected from (III), (IV), (V), (VI), (VII), (VIII), (IX) and (X) and Z is selected from groups of formula (XI), with the pharmaceutically acceptable salts and prodrugs of the aforesaid formula I or II final products being derived from the hereinbefore described Y and Z acid groups. These compounds are useful in treating aging skin, and also skin conditions such as psoriasis, acne and related disorder of keratinization and epithelial differentiation, as well as skin tumors.
Description
)93/06086 2 1 1 9 ~ 7 I Pcr/US92~0648s ~ `
RETINOIDS AND THEIR USE IN TREATING SKIN DISEASES AND LEUKEMIA
Technical Field The present invention relates to novel retinoids, methods for their preparation, pharmaceutical compositions comprising such compounds and the use of the compounds in0 treating the skin and in treating leukemia.
Background Art Caucasians who have had a good deal of sun exposure in childhood will show the following gross cutaneous alterations in adult life: wrinkling, leatheriness, yellowing, looseness, roughness, dryness, mottling (hyperpigmentation) and various premalignant growths (often subclinical). These changes are most prominent in light skinned persons who burn easily and tan poorly. The baleful e~fects of sunlight are cumulative, increasing with time.
Although the anatomic degradation of the skin is most advanced in the elderly, the destructive effects of excessive ~un exposure are already evident by the second decade. Serious microscopic alterations of the epidermis and dermis occur decades before these become clinically visible. Wrinkling, yellowing, leatheriness, and loss of elasticity are very late changes.
It is known to use vitamin A acid for the treatment of acne as set forth in U.S. Patent No. 3,729,568. Other known uses of vitamin A acid which were reviewed by Thomas and Doyle in the Journal of American Academy of Dermatoloay, 4, 505-513 (1981), include, in addition to acne treatment, treatment of senile comedones, nervus comedonicus, linear verrucous nevus, plantar warts, pseudofolliculitis, keratoacanthoma, solar keratosis of extremities, callosities, keratosis palmaris et plantaris, Darier's disease, ichthyosis, psoriasis, acanthosis nigricians, lichen planus, molluscum contagiosum, reactive perforating collagenosis, melasma, corneal epithelial healing, geographic tongue, Fox-Fordyce disease, cutaneous metastatic melanoma and keloids or hypertrophic scars. Vitamin A acid derivatives (retinoids) are known to have prophylactic and therapeutic effects on a great variety of tumors and are being increasingly used as anti-tumor drugs. The use of oral retinoic acid in treating leukemia has been reported by R. P. Warrell, Jr. et al., New England Journal of Medicine, 324, 1385-1393 (1991). Additionally, R.C. E~fland et al., in Published European Patent Application No. 043522A2 refer to the use of certain aminopyridinylmethanols and aminomethylpyridinamines as topical anti-inflammatory agents for the treatment of various dermatoses, while R. J. Yu et al. in U.S. Patent No. 4,141,977 discloses the use of several 6-nicotinamides and/or 2-substituted pyrizinamides as topical agents for the treatment of psoriasis.
Disclosure of the Invention The present invention relates to a compound of the formula:
r ~1 or a pharmaceutically acceptable salt or prodrug thereof, wherein Rl is Cl to C8 alkyl and Q is selected from .
O H H O
Il I . 1 11
RETINOIDS AND THEIR USE IN TREATING SKIN DISEASES AND LEUKEMIA
Technical Field The present invention relates to novel retinoids, methods for their preparation, pharmaceutical compositions comprising such compounds and the use of the compounds in0 treating the skin and in treating leukemia.
Background Art Caucasians who have had a good deal of sun exposure in childhood will show the following gross cutaneous alterations in adult life: wrinkling, leatheriness, yellowing, looseness, roughness, dryness, mottling (hyperpigmentation) and various premalignant growths (often subclinical). These changes are most prominent in light skinned persons who burn easily and tan poorly. The baleful e~fects of sunlight are cumulative, increasing with time.
Although the anatomic degradation of the skin is most advanced in the elderly, the destructive effects of excessive ~un exposure are already evident by the second decade. Serious microscopic alterations of the epidermis and dermis occur decades before these become clinically visible. Wrinkling, yellowing, leatheriness, and loss of elasticity are very late changes.
It is known to use vitamin A acid for the treatment of acne as set forth in U.S. Patent No. 3,729,568. Other known uses of vitamin A acid which were reviewed by Thomas and Doyle in the Journal of American Academy of Dermatoloay, 4, 505-513 (1981), include, in addition to acne treatment, treatment of senile comedones, nervus comedonicus, linear verrucous nevus, plantar warts, pseudofolliculitis, keratoacanthoma, solar keratosis of extremities, callosities, keratosis palmaris et plantaris, Darier's disease, ichthyosis, psoriasis, acanthosis nigricians, lichen planus, molluscum contagiosum, reactive perforating collagenosis, melasma, corneal epithelial healing, geographic tongue, Fox-Fordyce disease, cutaneous metastatic melanoma and keloids or hypertrophic scars. Vitamin A acid derivatives (retinoids) are known to have prophylactic and therapeutic effects on a great variety of tumors and are being increasingly used as anti-tumor drugs. The use of oral retinoic acid in treating leukemia has been reported by R. P. Warrell, Jr. et al., New England Journal of Medicine, 324, 1385-1393 (1991). Additionally, R.C. E~fland et al., in Published European Patent Application No. 043522A2 refer to the use of certain aminopyridinylmethanols and aminomethylpyridinamines as topical anti-inflammatory agents for the treatment of various dermatoses, while R. J. Yu et al. in U.S. Patent No. 4,141,977 discloses the use of several 6-nicotinamides and/or 2-substituted pyrizinamides as topical agents for the treatment of psoriasis.
Disclosure of the Invention The present invention relates to a compound of the formula:
r ~1 or a pharmaceutically acceptable salt or prodrug thereof, wherein Rl is Cl to C8 alkyl and Q is selected from .
O H H O
Il I . 1 11
- 2 5 --C--N--Y --N--C--Y
,,_ O O
--C--O--Y --O--C--Y
O O
--C--O--Z and --O--C--Z
wherein Y is selected from ;
SUBSTITUTE SHEET
~ , .. . .... . .
COOH
~ C O O H ~ C O O H ~ ~;~
5 ~(~3 C O O H ~ C O O H N~ C O O H N~
and Z is selected from groups of the formula:
~ COOH
with the pharmaceutically acceptable salt and prodrug of the formula I or II compound being derived from the aforesaid Y
and Z acid groups. These compounds are hereinafter also referred to as the active compounds of the present invention.
Preferred prodrugs of the present invention are compounds wherein Z is selected from groups of the formula:
~ COOR2 and Y is selected from groups of the formula:
~ CO~R2 ~ ~ COOR
~ C O O R 2 ~ C O O R z $~C O O R Z a n d wherein R2 is Cl to C8 alkyl, phenyl-CI to C8 alkyl or substituted phenyl-CI to C8 alkyl wherein the substituted phenyl may be substituted with one or two substituents selected from Cl to C4 alkyl and halogen (i.e. fluoro, chloro, bromo or iodo). Other prodrugs include compounds SUB~;TITUTE SHEET
1 1 3 ~; ~ !I r r r r ;
r O O
wherein R2 is -CH-o-C-R4 or -CH2-NHC-oR4 wherein R3 is H, CH3, l3 or C2H5 and R4 is Cl to C4 alkyl. Esters of alpha-amino penicillins having such R2 groups are disclosed in United States Patent 3,873,521.
The present invention also relates to the use of an amount of a compound of the formula I or II, including a pharmaceutically acceptable salt or prodrug thereof, effective in moderating or retarding the effects of aging of the skin and generally improving the quality of the skin or in treating conditions of the skin selected from the group consisting of psoriasis, acne and related disorders of keratinization and epithelial differentiation, and skin tumors.
The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a compound .of the formula I or II, including a pharmaceutically acceptable salt or prodrug thereof, effective in moderating or retarding the effects of aging of the skin and generally improving the quality of the skin or in treating conditions of the skin selected from the group consisting of psoriasis, acne and related disorders of keratinization.and epithelial differentiation, and skin tumors.
The present invention also relates to a pharmaceutical com~osition useful for treating leukemia comprising a pharmaceutically acceptable carrier and an amount of a compound of the formula- I or II, including a pharmaceutically acceptable salt or prodrug thereof, effective in halting or ameliorating the symptoms of leukemia. The composition is preferably administered as an oral dosage form.
The present in~ention also relates to a method for treating leukemia, which comprises administering to a patient in need of such treatment an amount of a compound of S~1BST~TU~: S~iE~
2 11~3 5 7 1 r r r r r the formula I or II, including a pharmaceutically acceptable salt or prodrug thereof, effective in halting or ameliorating the symptoms of leukemia.
The following are preferred compounds of the present 5 invention:
4 - ( 5 , 6 , 7 , 8 - t e t r a h y d r o - 5 , 5 , 8 , 8 - t e t r a m e t h y l - 2 -naphthoyloxy)-benzoic acid;
4- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyloxy-carbonyl)-benzoic acid;
6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8, -tetramethyl-2-naphthoylamino)-nicotinic acid; and 6- [ 3- ( 1-adamantyl) -4-methoxybenzoylamino ] -nicotinic acid .
Other specif ic compounds of the present invention are the following:
,,_ O O
--C--O--Y --O--C--Y
O O
--C--O--Z and --O--C--Z
wherein Y is selected from ;
SUBSTITUTE SHEET
~ , .. . .... . .
COOH
~ C O O H ~ C O O H ~ ~;~
5 ~(~3 C O O H ~ C O O H N~ C O O H N~
and Z is selected from groups of the formula:
~ COOH
with the pharmaceutically acceptable salt and prodrug of the formula I or II compound being derived from the aforesaid Y
and Z acid groups. These compounds are hereinafter also referred to as the active compounds of the present invention.
Preferred prodrugs of the present invention are compounds wherein Z is selected from groups of the formula:
~ COOR2 and Y is selected from groups of the formula:
~ CO~R2 ~ ~ COOR
~ C O O R 2 ~ C O O R z $~C O O R Z a n d wherein R2 is Cl to C8 alkyl, phenyl-CI to C8 alkyl or substituted phenyl-CI to C8 alkyl wherein the substituted phenyl may be substituted with one or two substituents selected from Cl to C4 alkyl and halogen (i.e. fluoro, chloro, bromo or iodo). Other prodrugs include compounds SUB~;TITUTE SHEET
1 1 3 ~; ~ !I r r r r ;
r O O
wherein R2 is -CH-o-C-R4 or -CH2-NHC-oR4 wherein R3 is H, CH3, l3 or C2H5 and R4 is Cl to C4 alkyl. Esters of alpha-amino penicillins having such R2 groups are disclosed in United States Patent 3,873,521.
The present invention also relates to the use of an amount of a compound of the formula I or II, including a pharmaceutically acceptable salt or prodrug thereof, effective in moderating or retarding the effects of aging of the skin and generally improving the quality of the skin or in treating conditions of the skin selected from the group consisting of psoriasis, acne and related disorders of keratinization and epithelial differentiation, and skin tumors.
The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a compound .of the formula I or II, including a pharmaceutically acceptable salt or prodrug thereof, effective in moderating or retarding the effects of aging of the skin and generally improving the quality of the skin or in treating conditions of the skin selected from the group consisting of psoriasis, acne and related disorders of keratinization.and epithelial differentiation, and skin tumors.
The present invention also relates to a pharmaceutical com~osition useful for treating leukemia comprising a pharmaceutically acceptable carrier and an amount of a compound of the formula- I or II, including a pharmaceutically acceptable salt or prodrug thereof, effective in halting or ameliorating the symptoms of leukemia. The composition is preferably administered as an oral dosage form.
The present in~ention also relates to a method for treating leukemia, which comprises administering to a patient in need of such treatment an amount of a compound of S~1BST~TU~: S~iE~
2 11~3 5 7 1 r r r r r the formula I or II, including a pharmaceutically acceptable salt or prodrug thereof, effective in halting or ameliorating the symptoms of leukemia.
The following are preferred compounds of the present 5 invention:
4 - ( 5 , 6 , 7 , 8 - t e t r a h y d r o - 5 , 5 , 8 , 8 - t e t r a m e t h y l - 2 -naphthoyloxy)-benzoic acid;
4- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyloxy-carbonyl)-benzoic acid;
6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8, -tetramethyl-2-naphthoylamino)-nicotinic acid; and 6- [ 3- ( 1-adamantyl) -4-methoxybenzoylamino ] -nicotinic acid .
Other specif ic compounds of the present invention are the following:
3- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoyloxy)-benzoic acid;
2- ( 5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2 -- naphthoyloxy)-benzoic acid;
6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoyloxy)-nicotinic acid;
3- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyloxy-carbonyl)-benzoic acid;
2- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyloxy-carbonyl)-benzoic acid;
6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyloxy-carbonyl ) -nicotinic acid;
5- ( S, 6, 7, 8-tetrahydro-5, 5, 8, 8 -tetramethyl-2 -naphthoylamino)-thiophene-2-carboxylic acid;
5- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoylamino)-nicotinic acid;
6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoylamino)-pyrazine-3-carboxylic acid;
2- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoylamino~-pyrimidine-5-carboxylic acid;
5-t3-(1-adamantyl)-4-methoxybenzoylamino~-thiophene-2-carboxylic acid;
S 7 ~
~ r ~
~ . r ~ ~ r r ~ . r , .
S-[3-(1-adamantyl)-4-methoxybenzoylamino]-nicotinic acid; -6-[3-(1-adamantyl)-4-methoxybenzoylamino]-pyrazine-3-carboxylic acid; and 2-[3-(1-adamantyl)-4-methoxybenzoylamino]-pyrimidine-S-carboxylic acid.
The present invention also relates to a compound of the formula:
HzNJ~COOR2 wherein R2 is Cl to C8 alkyl, phenyl-CI to C8 alkyl or substituted phenyl-CI to C8 alkyl wherein the substituted phenyl may be substituted with one or two substituents o selected from C~ to C4 alkyl and halogen, -CH-o-C-R4 or -CH2-NHC-oR4 wherein R3 is H, CH3, or C2H5 and R4 is Cl to C4 alkyl, which is useful in preparing compounds of the formulae I and II wherein Q is -~c--~ ~ coOQ2 wherein R2 is as defined above. Preferably R2 is C~ to C6 alkyl.
Detailed Description The active compounds of the present invention may be prepared as follows:
Amides are prepared by converting a dicarboxylic acid monoester derivative of the formula H02C-K-C02R2 wherein K is heteroarylene and R2 is as defined above to its acid chloride and reacting the acid chloride with an amine of the formula:
r r r ~ r ~ ~ ~ 1 ~ r ~ . r , ~ ~ .
~ r ~ ~ r r ~ ~ I
~NHZ ~l"NHz wherein R1 is C~ to C8 alkyl, or by reacting an amino acid ester of the formula H2N-K-C02R2 wherein K is heteroarylene and R2 is as defined above with an acid chloride of the formula:
COCI ~COCI
wherein Rl is C~ to C8 alkyl, in an inert solvent such as tetrahydrofuran and in the presence of a tertiary amine base, such as triethylamine, at a ~emperature of from about -20C to reflux, preferably at about 0C to room temperature, to yield compounds of the formulae-~NH-C--Y.--CO R2 [~l"NH-C--K--C02R2 ~,IC--NH-K--COzR~ C--NH-K--CO2RZ
Suitable solvents include tetrahydrofuran, diethylether, dimethylformamide or toluene. The preferred sol~ent is tetrahydrofuran. These intermediate compounds may then be saponified to the corresponding carboxylic acids by treatment with a base such as aqueous sodium hydroxide in a solvent such as tetrahydrofuran or ethanol to 5~J~35TlTUT 5H~El , ~ r ~ i r ~ -.. r give am des of the formulae I and II wherein Q is -C-NH-Y
or -NH-B-Y wherein Y is defined as above.
Esters of the formulae I or II are prepared by converting a dicarboxylic acid mono-benzylester of the formula HO2C-M-CO2CH2-phenyl wherein M is phenylene or heteroarylene to its acid chloride and reacting it with a hydroxy compound of the formula:
~OH ~"OH
or by reacting a hydroxy-acid benzyl ester of the formula HO-M-CO2CH2-phenyl wherein M is phenylene or heteroarylene with an acid chloride of the formula:
~ or ~ COCI
in either case in an inert solvent in the presence of a tertiary amine base, such as triethylamine, at a temperature between about -20C to reflux, preferably at room temperature, to yield intermediates of the formulae:
SUBSTITUTE SHEET
7 ~ ~ r ~ ~ ~ ~
. ~ ~ ~ ~ r ~ r r g ~0~l--C02CH2--pheny I, [~,0~--n~OzCH2~heny l, ~-0~1~02CH2--pheny I and ~-O-t1~02CH2--pheny I
Suitable solvents include tetrahydrofuran, diethylether, dimethylformamide, methylene chloride or toluene. The preferred solvent is tetrahydrofuran.
The intermediate compounds (which also can be considered prodrugs) can then be hydrogenated, .using a suitable catalyst such as palladium on carbon in an inert solvent, such as ethyl acetate, at temperatures between about 0 and about 50C and at a pressure between about 14 and about 50 psi to provide the final esters of formulae I
,_ O O , O
and II wherein Q is -COOY, -OC-Y, -C-O-Z or -O-C-Z, where Y and Z are as defined above.~ Other prodrugs wherein R2 is O O
-CH-o-C-R4 or -CH2-NHC-oR4 may be prepared from compounds of formulae I and II as outlined in U. S. Patent No. 3,873,521.
The compounds of the formulae I and II are carboxylic
2- ( 5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2 -- naphthoyloxy)-benzoic acid;
6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoyloxy)-nicotinic acid;
3- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyloxy-carbonyl)-benzoic acid;
2- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyloxy-carbonyl)-benzoic acid;
6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyloxy-carbonyl ) -nicotinic acid;
5- ( S, 6, 7, 8-tetrahydro-5, 5, 8, 8 -tetramethyl-2 -naphthoylamino)-thiophene-2-carboxylic acid;
5- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoylamino)-nicotinic acid;
6- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoylamino)-pyrazine-3-carboxylic acid;
2- (5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthoylamino~-pyrimidine-5-carboxylic acid;
5-t3-(1-adamantyl)-4-methoxybenzoylamino~-thiophene-2-carboxylic acid;
S 7 ~
~ r ~
~ . r ~ ~ r r ~ . r , .
S-[3-(1-adamantyl)-4-methoxybenzoylamino]-nicotinic acid; -6-[3-(1-adamantyl)-4-methoxybenzoylamino]-pyrazine-3-carboxylic acid; and 2-[3-(1-adamantyl)-4-methoxybenzoylamino]-pyrimidine-S-carboxylic acid.
The present invention also relates to a compound of the formula:
HzNJ~COOR2 wherein R2 is Cl to C8 alkyl, phenyl-CI to C8 alkyl or substituted phenyl-CI to C8 alkyl wherein the substituted phenyl may be substituted with one or two substituents o selected from C~ to C4 alkyl and halogen, -CH-o-C-R4 or -CH2-NHC-oR4 wherein R3 is H, CH3, or C2H5 and R4 is Cl to C4 alkyl, which is useful in preparing compounds of the formulae I and II wherein Q is -~c--~ ~ coOQ2 wherein R2 is as defined above. Preferably R2 is C~ to C6 alkyl.
Detailed Description The active compounds of the present invention may be prepared as follows:
Amides are prepared by converting a dicarboxylic acid monoester derivative of the formula H02C-K-C02R2 wherein K is heteroarylene and R2 is as defined above to its acid chloride and reacting the acid chloride with an amine of the formula:
r r r ~ r ~ ~ ~ 1 ~ r ~ . r , ~ ~ .
~ r ~ ~ r r ~ ~ I
~NHZ ~l"NHz wherein R1 is C~ to C8 alkyl, or by reacting an amino acid ester of the formula H2N-K-C02R2 wherein K is heteroarylene and R2 is as defined above with an acid chloride of the formula:
COCI ~COCI
wherein Rl is C~ to C8 alkyl, in an inert solvent such as tetrahydrofuran and in the presence of a tertiary amine base, such as triethylamine, at a ~emperature of from about -20C to reflux, preferably at about 0C to room temperature, to yield compounds of the formulae-~NH-C--Y.--CO R2 [~l"NH-C--K--C02R2 ~,IC--NH-K--COzR~ C--NH-K--CO2RZ
Suitable solvents include tetrahydrofuran, diethylether, dimethylformamide or toluene. The preferred sol~ent is tetrahydrofuran. These intermediate compounds may then be saponified to the corresponding carboxylic acids by treatment with a base such as aqueous sodium hydroxide in a solvent such as tetrahydrofuran or ethanol to 5~J~35TlTUT 5H~El , ~ r ~ i r ~ -.. r give am des of the formulae I and II wherein Q is -C-NH-Y
or -NH-B-Y wherein Y is defined as above.
Esters of the formulae I or II are prepared by converting a dicarboxylic acid mono-benzylester of the formula HO2C-M-CO2CH2-phenyl wherein M is phenylene or heteroarylene to its acid chloride and reacting it with a hydroxy compound of the formula:
~OH ~"OH
or by reacting a hydroxy-acid benzyl ester of the formula HO-M-CO2CH2-phenyl wherein M is phenylene or heteroarylene with an acid chloride of the formula:
~ or ~ COCI
in either case in an inert solvent in the presence of a tertiary amine base, such as triethylamine, at a temperature between about -20C to reflux, preferably at room temperature, to yield intermediates of the formulae:
SUBSTITUTE SHEET
7 ~ ~ r ~ ~ ~ ~
. ~ ~ ~ ~ r ~ r r g ~0~l--C02CH2--pheny I, [~,0~--n~OzCH2~heny l, ~-0~1~02CH2--pheny I and ~-O-t1~02CH2--pheny I
Suitable solvents include tetrahydrofuran, diethylether, dimethylformamide, methylene chloride or toluene. The preferred solvent is tetrahydrofuran.
The intermediate compounds (which also can be considered prodrugs) can then be hydrogenated, .using a suitable catalyst such as palladium on carbon in an inert solvent, such as ethyl acetate, at temperatures between about 0 and about 50C and at a pressure between about 14 and about 50 psi to provide the final esters of formulae I
,_ O O , O
and II wherein Q is -COOY, -OC-Y, -C-O-Z or -O-C-Z, where Y and Z are as defined above.~ Other prodrugs wherein R2 is O O
-CH-o-C-R4 or -CH2-NHC-oR4 may be prepared from compounds of formulae I and II as outlined in U. S. Patent No. 3,873,521.
The compounds of the formulae I and II are carboxylic
4~ acids and form salts with bases. Examples of these salts SUB~ T iTUTE SHEET
` ` ~ r r r ~ ;
are the salts with alkali metals such as sodium and potassium; or alkaline earth metals such as calcium, and magnesium; the salts with ammonia; and the salts with organic bases such as methylamine, ethylamine, diethylamine, trimethylamine, triethylamine, pyridine, picoline, arginine, lysine, triethanolamine, and meglumine. The salts are prepared by reacting a compound of the formulae I or II with 1 equivalent of base in a suitable inert solvent.
The active compounds of the present invention are useful in moderating and retarding the effects of aging of the skin and generally improving the quality of the skin, particularly huma~n facial skin, resulting in a more youthful appearance. The compounds may be administered by topical application beginning in middle age when aging changes first become evident clinically. Certain of the anatomic alterations may be corrected and at least partially reversed, accompanied by improvement in the appearance of the skin. More specffically, the compounds of the present invention have the following advantages inter alia:
Clinical Effacement of fine wrinkles Smoother surface Lighten pigmente~ blotches Skin has more turgor Large pores less noticeable Skin feels livelier and tighter Hi~oloaic Thicker epidermis Normalizes atypia and pre-malignant changes Atrophy and dysplasia corrected S~imulate blood flow; new vessels formed Stimulate fibroblasts with collagen formation Increase ground substance Melanin with keratinocytes is decreased The active compounds of the present invention suppress the hyperkeratinization of human tissue cells and are useful SUBSIITl~J~ SH~:ET
9 S ~7 1 r r ~ ~ r r in the systemic and topical treatment of dermatological ailments linked to a keratinization disorder (differentiation proliferation) or epithelial differentiation. They are also useful in treating S dermatologic ailments with inflammatory and/or immuno-allergic components (e.g., psoriasis and acne) and also have anti-tumoral activity. These compounds can also be employed in the treatment of cutaneous atrophy. These compounds are also usefully employed in the field of ophthalmology and principally in the treatment of corneopathy. Unless otherwise indicated, treatment can be systemic or topical.
Treatment of leukemia is generally systemic.
The effectiveness of the active sompounds of the present invention in retarding the effects of aging of the skin and generally improving the quality cf the skin may be evaluated in the rhino mouse model described below.
Three groups of mice, each having five mice are used.
One group receives test agent, one group receives vehicle, and the third group is untreated. The mice used are female rhino (age about 7 weeks). The dorsal surface of each animal is treated with 100 ~1 of topical agents, once a day,
` ` ~ r r r ~ ;
are the salts with alkali metals such as sodium and potassium; or alkaline earth metals such as calcium, and magnesium; the salts with ammonia; and the salts with organic bases such as methylamine, ethylamine, diethylamine, trimethylamine, triethylamine, pyridine, picoline, arginine, lysine, triethanolamine, and meglumine. The salts are prepared by reacting a compound of the formulae I or II with 1 equivalent of base in a suitable inert solvent.
The active compounds of the present invention are useful in moderating and retarding the effects of aging of the skin and generally improving the quality of the skin, particularly huma~n facial skin, resulting in a more youthful appearance. The compounds may be administered by topical application beginning in middle age when aging changes first become evident clinically. Certain of the anatomic alterations may be corrected and at least partially reversed, accompanied by improvement in the appearance of the skin. More specffically, the compounds of the present invention have the following advantages inter alia:
Clinical Effacement of fine wrinkles Smoother surface Lighten pigmente~ blotches Skin has more turgor Large pores less noticeable Skin feels livelier and tighter Hi~oloaic Thicker epidermis Normalizes atypia and pre-malignant changes Atrophy and dysplasia corrected S~imulate blood flow; new vessels formed Stimulate fibroblasts with collagen formation Increase ground substance Melanin with keratinocytes is decreased The active compounds of the present invention suppress the hyperkeratinization of human tissue cells and are useful SUBSIITl~J~ SH~:ET
9 S ~7 1 r r ~ ~ r r in the systemic and topical treatment of dermatological ailments linked to a keratinization disorder (differentiation proliferation) or epithelial differentiation. They are also useful in treating S dermatologic ailments with inflammatory and/or immuno-allergic components (e.g., psoriasis and acne) and also have anti-tumoral activity. These compounds can also be employed in the treatment of cutaneous atrophy. These compounds are also usefully employed in the field of ophthalmology and principally in the treatment of corneopathy. Unless otherwise indicated, treatment can be systemic or topical.
Treatment of leukemia is generally systemic.
The effectiveness of the active sompounds of the present invention in retarding the effects of aging of the skin and generally improving the quality cf the skin may be evaluated in the rhino mouse model described below.
Three groups of mice, each having five mice are used.
One group receives test agent, one group receives vehicle, and the third group is untreated. The mice used are female rhino (age about 7 weeks). The dorsal surface of each animal is treated with 100 ~1 of topical agents, once a day,
5 times a week for 4 weeks. - At the end of the treatment period, animals are clinically assessed for effacement of skin folds and wrinkles. Representative animals are photographed with untreated controls.
For histologic evaluation, dorsal skin biopsies (strips about 1 cm long) are processed for light microscopy.
Sections are evaluated on an ordinal scale for normalization of the epidermis and utriculi (abnormal hair follicles~.
For the split skin assessment, a 2 cm2 portion of dorsal skin is excised. Epidermis is separated from the dermis with 0.5% acetic acid and processed for light microscopy and microphotography. Utriculi are measured from the photographs for numerical data (mean + S.D.).
The active compounds of this invention may be tested according to the following procedùre which shows the differentiation of malignant cells, whereby the SUBSTITUTE SHEET
r ~ r ~ r r ~ r r ~ ~` ~
r differentiation of human acute promyelocytic leukemia cells (HL-60) and their conversion to mature granulocytes (myelocytes) can be assayed by an observation of the morphological changes of nuclei and further by the measurement of the degree of reduction of nitro-blue tetrazolium (NBT) which is induced by a test compound tProc.
Natl. Acad. Sci. U.S.A., 77, 2936-2940 (1980)~.
The HL-60 cells are cultured in plastic flasks in RPMI-1640 medium supplemented with 5% heat inactivated fetal calf seru~ and antibiotics (penicillin G and streptomycin). The cells (3xlO4/ml) are then cultured with a compound of the present invention for 4 days. Growth inhibition of the cells by the test compounds is then determined by counting the number of cells by microscope and relative ratio was e:camined by taking the number of cells by control (without test compoundj as 100%. The cells are fixed and stained with Wright-Giemsa stain to examine the morphological changes of the nuclei;
The cells treated with the present compounds are differentiated -to mature granulocytes (myelocytes, metamyelocytes and neutrophils), just as the cells treated with retinoic acid. The biochemical activity of cells treated with the compound is measured as follows:
The cells after 5 days incubation are centrifuged and diluted with RPMI-1640 medium supplemented with 5% fetal calf serum, to provide a definite number of the cells. To the diluted cell suspension are then added 200 mg/ml of 12-O-tetradodecanoylphorbol-13-acetate (TPA) and the resulting culture medium is then incubated for 20 minutes at 370C in the presence of 0.1% of NBT. Thus, the mature differentiated cells containing blue-black formazan are counted by microscopy, so that the ratio of the cells having ~he ability to reduce N8T, to total cells, can be calculated.
The active compounds of the present invention can be used for determining the type of leukemia a patient may have by incubating a sample of a patient's blood in vitro in the S~JBS I ITIITF C~
3 lj 7 r ~ r ~ ~ ~ ~ r r ~ ~ ~ r r r presence of a compound of the present invention in ananalogous manner as described in the morphological assay for the HL-60 cells: Only promyelocytic leukemia cells, but no lymphocytic leukemia cells, differentiate to mature granulocytes, which can be clearly determined by observation with a microscope [Sabo in Cells, 14, 533 ~1982)~. When the incubation is performed in a soft agar, promyelocytic leukemia cells do not form a colony, since the differentiated cells do not proliferate further. Thus, these compounds are very useful in the determination of promyelocytic leukemia, which enables one to select the appropriate therapeutic method.
The antileukemic activity of the active compounds of the present invention may be demonstrated by testing for their ability to treat HL-60 (human derived leukemia cells) nude mice by the following procedure:
A test compound is suspended in 10% (v/v) Tween 80 (trademark) in a concentration of 10 mg/ml. Cells (sxlo7) of HL-60 are transplanted subcutaneously to a nude mouse ~;
(BALB/c, nu/nu female Nihon Clea). At the end of days 9, 14 and 17 after the transplantation, 0.1 ml of the suspension per 10 g of body weight of mouse are administered pQr os two time5 at intervals of 7 hours (200 mg/kg/day). Tumor volumes are measured after 4, 6, 8 and 11 days after the first administration. Compounds effective against HL-60 cells are also expected to be effective against neuroblastoma, squamous cells carcinoma, and melanoma.
The pharmaceutical compositions containing the active compounds of the present invention as the main component are formulated in a conventional manner, using conventional carriers for formulation, including ~excipients. The medicaments may be administered orally as tablets, pills, capsules, granules, etc., or may be administered parenterally as injections such as intravenous injections, intramuscular injections, etc., in the form of ointments, creams and the like for external application in particular for the treatment of dermatological disorders. They may be S~5~S J ~TUT~ SHE:;T
" ~ ' ,, r, ~ r ,. ~ r ~ ~ r r ~ ~ r ~
r ~ r ~ .
used as aerosols, suppositories, etc. The doses of the medicaments are properly determined according to each case on considering the symptom, the age of patient, sex, etc., but are usually about 1 to about 300 mg per day for an adult in case of oral administration and about 1 to about 100 mg per day for an adult in case of parenteral administration, the daily amount usually being administered in 2 or 3 separate dosages.
The active compounds of the present invention retard the effects of normal aging of the skin due to impairment of the differentiation of epidermal epithelial cells and due to loss of collagen fibers, abnormal changes in the elastic fibers and deterioration of small blood vessels of the dermis of the skin. The compounds are applied topically to the epidermis of the skin in a program of maintenance therapy, whereby epithelial growths are substantially reduced and prevented and the skin substantially regains and maintains its firmness, turgor and elasticity during the the~apy. Generally, the maintenance therapy is begun in middle age when epithelial growths and other aging changes begin to appear clinically. For topical application, the active compounds of the present invention may be applied to the skin in any suitable non-toxic, dermatologically acceptable vehicle (preferably a non-volatile, emollient or lub~icating vehicle, such as an oleaginous substance, which helps hydrate the skin) in an amount and at a frequency which are insufficient to cause excessive irritation of the . _ .
skin. Generally, concentrations in the range of about 0.0005 to about 0.05% and pr ferably, from about 0.005~ to about 0.025% by weight of the vehicle are preferred.
Various non-toxic, dermatologically acceptable vehicles or carriers will be evident to those of ordinary skill in - the art. Volatile vehicles which dry or otherwise harm the skin, such as alcohol and acetone, should be avoided. An ointment base (without water) is preferred in the winter and in subjects with very dry skin. Examples of suitable ointment bases are petrolatum, petrolatum plus volatile SUBSTIT~JTE SHEET
7~
~ ,. . . . . . . . .
r silicones, and lanolin. In warm weather and often for younger persons, emulsion (cream) bases, which are mixtures of oils and water are preferred. Examples of suitable cream bases are Eucerin (trademark, Beiersdorf), cold cream (USP), S Purpose Cream (trademark, Johnson ~ Johnson) and hydrophilic ointment (USP).
The treatment according to the present invention relating to aging of the skin is intended to continue indefinitely; otherwise, the effects of aging may reappear after treatment is terminated. That is, the treatment of the present invention may be considered to be intervention therapy in decelerating the aging process. If the intervention is stopped, there may be regression to the original state.
lS Usuall~, there is little point in beginning the treatments of the present invention relating to aging until middle age when the effects of aging begin to appear. The particular program of maintenance therapy according to the present invention will vary depending upon the individual being treated. Generally, depending upon the age and state of the skin when treatments begin, once a day applications for up to 6 months may be necessary to reduce and control the effects of aging which have already occurred. Once a stabilized sXin control has been obtained, the frequency of 25- application of an active compound of the present invention may be reduced, for example, to two or three times a week, and in some cases only once a week for the rest of the person's life. That is, once the aging process has been controlled, a maintenance dose on the order of two applications per week may be sufficient to maintain that state.
SUB~ T IT~l E SHEE:T
7 ~
.. ... . . . .. . . . .
~' ~ ' ~ r r . ..
~ . ~ ~ ~ r ~ ~ r . I
4-(5,6 7,~-Tetrahydrc-5 5,8.8-tetramethyl-2-naphthoyl-oxy)-benzoic acid A 500 ml three-neck round-bottom flask equipped with a stirrer and a condenser was charged with 5.0 g (0.0217 mole) of 2-acetyl-5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-naphthalene and 261.1 ml of a 3~ NaOCl solution ~149.1 ml of 5.25% NaOCl (Clorox) (trademark)], and combined with 112 ml water and 4.7 ml of a 45% aqueous KOH solution. The mixture was heated with an oil bath to reflux under stirring for 2 hours, allowed to cool to room temperature and extracted with ethyl acetate. The aqueous layer was acidified with lN
HCl and the precipitated product was extracted with ethyl acetate. This organic layer was then washed with water and with saturated sodium chloride solution, dried over anhydrous sodium sulfate and evaporated in vacuo to give, after trituration with petroleum ether, 4.0 g (79%) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoic acid, mp 174-6C; MS: m/e, 232; NMR (CDCl3) consistent with product.
Anal.: Calcd. for C15H20O2: C, 75.55; H, 8.68; Found: C, 76.01;
H, 8.40.
A 50 ml three-neck round-bottom flas~ equipped with a stirrer, a condenser and a nitrogen inlet tube was charged with 2.15 g (0.00927 mole) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoic acid (prepared as described above), 5 ml (8 g; 0.067 mole) of thionyl chloride and a catalytic amount of pyridine. The resulting orange solution was hea~ed at reflux for 2.5 hours, cvoled and evaporated in vacuo to give the acid chloride as an orange-brown oil. A
250 ml three-neck round-bottom flask equipped with a stirrer, condenser and a nitrogen inlet tube was charged with a solution of 2.11 g (0.00925 mole) of benzyl 4-hydroxybenzoate in 50 ml of dry tetrahydrofuran, cooled to 0C in an ice-bath, at which point 1.3 ml (0.934 g; 0.00g25 mole) of triethylamine and then the acid chloride prepared above (slurried in 50 ml of tetrahydrofuran) were added.
The mixture was heated under stirring to 60C for 5 hours 5'~ 1 lT'~3~ S~
~ 9 ~ 7 ~
~, . ~, , .
.
and then kept at room temperature overnight. After evaporation of the solvent in vacuo, the residue was taken up in ethyl acetate/water, the organic layer was washed with water, dried over anhydrous sodium sulfate and then S evaporated in vacuo to a yellow solid. This solid was dissolved in 30 ml of tetrahydrofuran, 10% Pd/C was added and the mixture was hydrogenated at 10 psi on a Parr shaker for 2.5 hours, and then hydrogenated with fresh catalyst for another hour when TLC (thin layer chromatography) analysis (ethyl acetate) indicated the reaction to be complete. The catalyst was removed by filtration over diatomaceous earth tCelite(trademark)] and washed with ethyl acetate, the filtrate was evaporated in vacuo and the residual white solid (2.6 g) recrystallized from absolute ethanol to give 1.39 g (43%) of 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoyloxy)-benzoic acid as white crystals, mp > 230C;
MS: m/e, 352; NMR (DMS0-d6) consistent with product. Anal.
Calcd. for C22H24O4:;C, 74.98; H, 6.86. Found: C, 75.14; H,
For histologic evaluation, dorsal skin biopsies (strips about 1 cm long) are processed for light microscopy.
Sections are evaluated on an ordinal scale for normalization of the epidermis and utriculi (abnormal hair follicles~.
For the split skin assessment, a 2 cm2 portion of dorsal skin is excised. Epidermis is separated from the dermis with 0.5% acetic acid and processed for light microscopy and microphotography. Utriculi are measured from the photographs for numerical data (mean + S.D.).
The active compounds of this invention may be tested according to the following procedùre which shows the differentiation of malignant cells, whereby the SUBSTITUTE SHEET
r ~ r ~ r r ~ r r ~ ~` ~
r differentiation of human acute promyelocytic leukemia cells (HL-60) and their conversion to mature granulocytes (myelocytes) can be assayed by an observation of the morphological changes of nuclei and further by the measurement of the degree of reduction of nitro-blue tetrazolium (NBT) which is induced by a test compound tProc.
Natl. Acad. Sci. U.S.A., 77, 2936-2940 (1980)~.
The HL-60 cells are cultured in plastic flasks in RPMI-1640 medium supplemented with 5% heat inactivated fetal calf seru~ and antibiotics (penicillin G and streptomycin). The cells (3xlO4/ml) are then cultured with a compound of the present invention for 4 days. Growth inhibition of the cells by the test compounds is then determined by counting the number of cells by microscope and relative ratio was e:camined by taking the number of cells by control (without test compoundj as 100%. The cells are fixed and stained with Wright-Giemsa stain to examine the morphological changes of the nuclei;
The cells treated with the present compounds are differentiated -to mature granulocytes (myelocytes, metamyelocytes and neutrophils), just as the cells treated with retinoic acid. The biochemical activity of cells treated with the compound is measured as follows:
The cells after 5 days incubation are centrifuged and diluted with RPMI-1640 medium supplemented with 5% fetal calf serum, to provide a definite number of the cells. To the diluted cell suspension are then added 200 mg/ml of 12-O-tetradodecanoylphorbol-13-acetate (TPA) and the resulting culture medium is then incubated for 20 minutes at 370C in the presence of 0.1% of NBT. Thus, the mature differentiated cells containing blue-black formazan are counted by microscopy, so that the ratio of the cells having ~he ability to reduce N8T, to total cells, can be calculated.
The active compounds of the present invention can be used for determining the type of leukemia a patient may have by incubating a sample of a patient's blood in vitro in the S~JBS I ITIITF C~
3 lj 7 r ~ r ~ ~ ~ ~ r r ~ ~ ~ r r r presence of a compound of the present invention in ananalogous manner as described in the morphological assay for the HL-60 cells: Only promyelocytic leukemia cells, but no lymphocytic leukemia cells, differentiate to mature granulocytes, which can be clearly determined by observation with a microscope [Sabo in Cells, 14, 533 ~1982)~. When the incubation is performed in a soft agar, promyelocytic leukemia cells do not form a colony, since the differentiated cells do not proliferate further. Thus, these compounds are very useful in the determination of promyelocytic leukemia, which enables one to select the appropriate therapeutic method.
The antileukemic activity of the active compounds of the present invention may be demonstrated by testing for their ability to treat HL-60 (human derived leukemia cells) nude mice by the following procedure:
A test compound is suspended in 10% (v/v) Tween 80 (trademark) in a concentration of 10 mg/ml. Cells (sxlo7) of HL-60 are transplanted subcutaneously to a nude mouse ~;
(BALB/c, nu/nu female Nihon Clea). At the end of days 9, 14 and 17 after the transplantation, 0.1 ml of the suspension per 10 g of body weight of mouse are administered pQr os two time5 at intervals of 7 hours (200 mg/kg/day). Tumor volumes are measured after 4, 6, 8 and 11 days after the first administration. Compounds effective against HL-60 cells are also expected to be effective against neuroblastoma, squamous cells carcinoma, and melanoma.
The pharmaceutical compositions containing the active compounds of the present invention as the main component are formulated in a conventional manner, using conventional carriers for formulation, including ~excipients. The medicaments may be administered orally as tablets, pills, capsules, granules, etc., or may be administered parenterally as injections such as intravenous injections, intramuscular injections, etc., in the form of ointments, creams and the like for external application in particular for the treatment of dermatological disorders. They may be S~5~S J ~TUT~ SHE:;T
" ~ ' ,, r, ~ r ,. ~ r ~ ~ r r ~ ~ r ~
r ~ r ~ .
used as aerosols, suppositories, etc. The doses of the medicaments are properly determined according to each case on considering the symptom, the age of patient, sex, etc., but are usually about 1 to about 300 mg per day for an adult in case of oral administration and about 1 to about 100 mg per day for an adult in case of parenteral administration, the daily amount usually being administered in 2 or 3 separate dosages.
The active compounds of the present invention retard the effects of normal aging of the skin due to impairment of the differentiation of epidermal epithelial cells and due to loss of collagen fibers, abnormal changes in the elastic fibers and deterioration of small blood vessels of the dermis of the skin. The compounds are applied topically to the epidermis of the skin in a program of maintenance therapy, whereby epithelial growths are substantially reduced and prevented and the skin substantially regains and maintains its firmness, turgor and elasticity during the the~apy. Generally, the maintenance therapy is begun in middle age when epithelial growths and other aging changes begin to appear clinically. For topical application, the active compounds of the present invention may be applied to the skin in any suitable non-toxic, dermatologically acceptable vehicle (preferably a non-volatile, emollient or lub~icating vehicle, such as an oleaginous substance, which helps hydrate the skin) in an amount and at a frequency which are insufficient to cause excessive irritation of the . _ .
skin. Generally, concentrations in the range of about 0.0005 to about 0.05% and pr ferably, from about 0.005~ to about 0.025% by weight of the vehicle are preferred.
Various non-toxic, dermatologically acceptable vehicles or carriers will be evident to those of ordinary skill in - the art. Volatile vehicles which dry or otherwise harm the skin, such as alcohol and acetone, should be avoided. An ointment base (without water) is preferred in the winter and in subjects with very dry skin. Examples of suitable ointment bases are petrolatum, petrolatum plus volatile SUBSTIT~JTE SHEET
7~
~ ,. . . . . . . . .
r silicones, and lanolin. In warm weather and often for younger persons, emulsion (cream) bases, which are mixtures of oils and water are preferred. Examples of suitable cream bases are Eucerin (trademark, Beiersdorf), cold cream (USP), S Purpose Cream (trademark, Johnson ~ Johnson) and hydrophilic ointment (USP).
The treatment according to the present invention relating to aging of the skin is intended to continue indefinitely; otherwise, the effects of aging may reappear after treatment is terminated. That is, the treatment of the present invention may be considered to be intervention therapy in decelerating the aging process. If the intervention is stopped, there may be regression to the original state.
lS Usuall~, there is little point in beginning the treatments of the present invention relating to aging until middle age when the effects of aging begin to appear. The particular program of maintenance therapy according to the present invention will vary depending upon the individual being treated. Generally, depending upon the age and state of the skin when treatments begin, once a day applications for up to 6 months may be necessary to reduce and control the effects of aging which have already occurred. Once a stabilized sXin control has been obtained, the frequency of 25- application of an active compound of the present invention may be reduced, for example, to two or three times a week, and in some cases only once a week for the rest of the person's life. That is, once the aging process has been controlled, a maintenance dose on the order of two applications per week may be sufficient to maintain that state.
SUB~ T IT~l E SHEE:T
7 ~
.. ... . . . .. . . . .
~' ~ ' ~ r r . ..
~ . ~ ~ ~ r ~ ~ r . I
4-(5,6 7,~-Tetrahydrc-5 5,8.8-tetramethyl-2-naphthoyl-oxy)-benzoic acid A 500 ml three-neck round-bottom flask equipped with a stirrer and a condenser was charged with 5.0 g (0.0217 mole) of 2-acetyl-5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-naphthalene and 261.1 ml of a 3~ NaOCl solution ~149.1 ml of 5.25% NaOCl (Clorox) (trademark)], and combined with 112 ml water and 4.7 ml of a 45% aqueous KOH solution. The mixture was heated with an oil bath to reflux under stirring for 2 hours, allowed to cool to room temperature and extracted with ethyl acetate. The aqueous layer was acidified with lN
HCl and the precipitated product was extracted with ethyl acetate. This organic layer was then washed with water and with saturated sodium chloride solution, dried over anhydrous sodium sulfate and evaporated in vacuo to give, after trituration with petroleum ether, 4.0 g (79%) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoic acid, mp 174-6C; MS: m/e, 232; NMR (CDCl3) consistent with product.
Anal.: Calcd. for C15H20O2: C, 75.55; H, 8.68; Found: C, 76.01;
H, 8.40.
A 50 ml three-neck round-bottom flas~ equipped with a stirrer, a condenser and a nitrogen inlet tube was charged with 2.15 g (0.00927 mole) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoic acid (prepared as described above), 5 ml (8 g; 0.067 mole) of thionyl chloride and a catalytic amount of pyridine. The resulting orange solution was hea~ed at reflux for 2.5 hours, cvoled and evaporated in vacuo to give the acid chloride as an orange-brown oil. A
250 ml three-neck round-bottom flask equipped with a stirrer, condenser and a nitrogen inlet tube was charged with a solution of 2.11 g (0.00925 mole) of benzyl 4-hydroxybenzoate in 50 ml of dry tetrahydrofuran, cooled to 0C in an ice-bath, at which point 1.3 ml (0.934 g; 0.00g25 mole) of triethylamine and then the acid chloride prepared above (slurried in 50 ml of tetrahydrofuran) were added.
The mixture was heated under stirring to 60C for 5 hours 5'~ 1 lT'~3~ S~
~ 9 ~ 7 ~
~, . ~, , .
.
and then kept at room temperature overnight. After evaporation of the solvent in vacuo, the residue was taken up in ethyl acetate/water, the organic layer was washed with water, dried over anhydrous sodium sulfate and then S evaporated in vacuo to a yellow solid. This solid was dissolved in 30 ml of tetrahydrofuran, 10% Pd/C was added and the mixture was hydrogenated at 10 psi on a Parr shaker for 2.5 hours, and then hydrogenated with fresh catalyst for another hour when TLC (thin layer chromatography) analysis (ethyl acetate) indicated the reaction to be complete. The catalyst was removed by filtration over diatomaceous earth tCelite(trademark)] and washed with ethyl acetate, the filtrate was evaporated in vacuo and the residual white solid (2.6 g) recrystallized from absolute ethanol to give 1.39 g (43%) of 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoyloxy)-benzoic acid as white crystals, mp > 230C;
MS: m/e, 352; NMR (DMS0-d6) consistent with product. Anal.
Calcd. for C22H24O4:;C, 74.98; H, 6.86. Found: C, 75.14; H,
6.69.
4-(5 6 7 8-TetrahYdro-5r5 8 8-tetramethyl-2-naphthyl-ox~y-carbonvl)-benzoic acid A 50 ml three-neck round bottom flask equipped with a stirrer, a condenser and a nitrogen inlet tube was charged with 0.4 g (O.OOlS6 mole) of terephthalic acid mono-benzyl ester tprepared according to G. J. Atwell and B. F. Cain, in J. Med. Chem., 10, 706 (1967)], l.lS ml (1.86 g; 0.0156 mole) of thionyl chloride and a catalytic amount of pyridine. The mixture was heated at reflux for 2 hours.
The solution was then kept at 650C overnight, cooled and evaporated in vacuo to give the acid chloride as a yellow semi-solid. A 50 ml three-neck round-bottom flask equipped with a stirrer, condenser and a nitrogen inlet tube was charged with a slurry of 0.305g (O.OOlS mole) of S,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol ~prepared according to H.A. Bruson and J.W. Kroeger, J. Am. Chem.
Soc~., 62, 36 (1940)] in 25 ml of dry tetrahydrofuran, 0.207 5~ 1T~JTE SHEET
3 7 i~
r r r ml (0.15 g; 0.0015 mole) of triethylamine and 0.410 g (0.0015 mole) of the acid chloride prepared above. The mixture was heated under stirring to reflux for 2 hours and then kept at 50OC overnight, at which point TLC analysis (hexane/ethyl acetate 1:1) indicated that the reaction was complete. After evaporation of the solvent in vacuo, the residue was taken up in ethyl acetate/water, the organic layer was washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo to give, after trituration with hexane, 230 mg (35%) of a white solid; MS: m/e, 442;
NMR (DMSO-d6) consistent with product. This solid was dissolved in 30 ml of ethyl acetate, 10~ Pd/C was added and the mixture was hydrogenated at 40 psi on a Parr shaker for 4 hours when TLC analysis (hexane/ethyl acetate 1:1) indicated that the reaction was complete. The catalyst was removed by filtration over diatomaceous earth ~Celite (trademark)] and washed with ethyl acetate, the filtrate was evaporated in vacuo and the residual white solid triturated with hexane to give 85 mg t46%) of the title compound as white crystals, mp > 2-20C; MS: m/e, 3S2; NMR (DMS0-~) consistent with product; Anal. Calcd. for CnH24O2: C, 74.98;
H, 6.86. Found: C, 74.50; ~, 6.59.
6-(5 6 7 8-Tetrahydro-5 5 8 8-tetramethyl-2-na~hthoyl-amino)-nicotinic acid A 500 ml three-neck round-bottom flask equipped with a stirrer and a condenser was charged with 11.81 g (0.085 mo~é) of 6-aminonicotinic acid and 60 m~ of thionyl chloride; 5 ml of pyridine were then added and the mixture was refluxed under stirring for l hour. After evaporation in vacuo, the residual orange-brown oil was cooled to ooc and carefully treated with 50 ml of methanol. After the slight exotherm subsided, the yellow solution was evaporated ia vacuo and the residue was taken up in ethyl acetate/water. The organic layer was washed with aqueous sodium bicarbonate solution and water, dried over anhydrous sodium sulfate and evaporated in yacuo to give, after ~STIT~JTE S~.~EET
4-(5 6 7 8-TetrahYdro-5r5 8 8-tetramethyl-2-naphthyl-ox~y-carbonvl)-benzoic acid A 50 ml three-neck round bottom flask equipped with a stirrer, a condenser and a nitrogen inlet tube was charged with 0.4 g (O.OOlS6 mole) of terephthalic acid mono-benzyl ester tprepared according to G. J. Atwell and B. F. Cain, in J. Med. Chem., 10, 706 (1967)], l.lS ml (1.86 g; 0.0156 mole) of thionyl chloride and a catalytic amount of pyridine. The mixture was heated at reflux for 2 hours.
The solution was then kept at 650C overnight, cooled and evaporated in vacuo to give the acid chloride as a yellow semi-solid. A 50 ml three-neck round-bottom flask equipped with a stirrer, condenser and a nitrogen inlet tube was charged with a slurry of 0.305g (O.OOlS mole) of S,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthol ~prepared according to H.A. Bruson and J.W. Kroeger, J. Am. Chem.
Soc~., 62, 36 (1940)] in 25 ml of dry tetrahydrofuran, 0.207 5~ 1T~JTE SHEET
3 7 i~
r r r ml (0.15 g; 0.0015 mole) of triethylamine and 0.410 g (0.0015 mole) of the acid chloride prepared above. The mixture was heated under stirring to reflux for 2 hours and then kept at 50OC overnight, at which point TLC analysis (hexane/ethyl acetate 1:1) indicated that the reaction was complete. After evaporation of the solvent in vacuo, the residue was taken up in ethyl acetate/water, the organic layer was washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo to give, after trituration with hexane, 230 mg (35%) of a white solid; MS: m/e, 442;
NMR (DMSO-d6) consistent with product. This solid was dissolved in 30 ml of ethyl acetate, 10~ Pd/C was added and the mixture was hydrogenated at 40 psi on a Parr shaker for 4 hours when TLC analysis (hexane/ethyl acetate 1:1) indicated that the reaction was complete. The catalyst was removed by filtration over diatomaceous earth ~Celite (trademark)] and washed with ethyl acetate, the filtrate was evaporated in vacuo and the residual white solid triturated with hexane to give 85 mg t46%) of the title compound as white crystals, mp > 2-20C; MS: m/e, 3S2; NMR (DMS0-~) consistent with product; Anal. Calcd. for CnH24O2: C, 74.98;
H, 6.86. Found: C, 74.50; ~, 6.59.
6-(5 6 7 8-Tetrahydro-5 5 8 8-tetramethyl-2-na~hthoyl-amino)-nicotinic acid A 500 ml three-neck round-bottom flask equipped with a stirrer and a condenser was charged with 11.81 g (0.085 mo~é) of 6-aminonicotinic acid and 60 m~ of thionyl chloride; 5 ml of pyridine were then added and the mixture was refluxed under stirring for l hour. After evaporation in vacuo, the residual orange-brown oil was cooled to ooc and carefully treated with 50 ml of methanol. After the slight exotherm subsided, the yellow solution was evaporated ia vacuo and the residue was taken up in ethyl acetate/water. The organic layer was washed with aqueous sodium bicarbonate solution and water, dried over anhydrous sodium sulfate and evaporated in yacuo to give, after ~STIT~JTE S~.~EET
7 1 .. . . . ..
r r r ' crystallization of the residue from chloroform/hexane, 8.71 g (65%) of methyl 6-aminonicotinate, mp 153-155C; MS: m/e, 152; NMR (CDCl3j consistent with product.
A 500 ml three-neck round-bottom flask equipped with a stirrer and a condenser was charged with 7.67 g (0.049 mole) of methyl 6-aminonicotinate (prepared as described above) and 150 ml of tetrahydrofuran; 6.81 ml (4.96 g; 0.049 mole) of triethylamine and 12.29 g (0.049 mole) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoylchloride(prepared as described in Example 1) were then added and the mixture stirred at room temperature overnight. After evaporation in vacuo, the residue was partitioned between water and ethyl acetate, the organic layer was washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica, using hexane/ethyl acetate as the eluant. The major LP spot wa~ collected to give a tan solid [NMR (CDCl3) consistent with the methyl es~er of the desired product]. This material was dissoived in 50 ml of tetrahydrofuran, 50 ml of 2N NaOH was added and the mixture was stirred at room - temperature overnight. After partial evaporation ln vacuo to remove the organic solvent, the aqueous solution was acidified to pH 4 with 6N HCl to give a cream-colored precipitate, which was filtered and recrystallized from ethanol to afford 6.32 g (37%) of the title compound as white crystals, mp > 240C; MS: m/e, 352; NMR (DMSO-d6) consistent with product. Anal. Calcd. for ~H~N2O3: C, 71.56; H, 6.86; N, 7.95. Found: C, 71.24; H, 7.11; N, 7.87.
6-r3-(1-AdamantYl)-4-methoxv-benzoylamino1-nicotinic acid A 150 mL three-neck round-bottom flask equipped with a stirrer and a condenser was charged with 250 mg (0.0016 mole) of methyl 6-aminonicotinate (prepared as described in Example 3) and 15 mL of tetrahydrofuran; 0.23 mL (0.16 g;
0.0016 mole) of triethylamine and 0.5 g (0.0016 mole) of 3-~1-adamantyl)-4-methoxybenzoyl c~loride (prepared according 5~33~1TlJIE S~?FT
,~
a, ~
~ ~ ~ . . .. . .
~ ~ r ~ ' ' ' to the method of B. Shroot et al., as described in U.S.
Patent No. 4,927,928) were then added and the mixture stirred at room temperature overnight. After evaporation in vacuo, the residue was partitioned between water and ethyl acetate, the organic layer was washed with water and brine, dried over anhydrous and evaporated in vacuo. The residue was purified by column chromatography on silica, using hexane/ethyl acetate as the eluant. The major and less lipophilic spot was collected to give a tan solid tNMR
(CDCl3) consistent with methyl ester of the desired product].
This material was dissolved in 5 mL of tetrahydrofuran, 3 mL
of 2N aqueous NaOH were added and the mixture was stirred at room temperature overnight. After partial evaporation n vacuo to remove the organic solvent, the aqueous solution was acidified to pH 4 with 6N HCl to give a white precipitate, which was filtered and recrystallized from ethanol to afford 203 mg (31%) of the title compound as white crystals, mp >250C; MS: m/e, 406; NMR (DMSO-d6) consistent with product. Anal. Calcd. for C24H26N2O4-H2O: C, 67.91; H, 6.65; N, 6.60. Found: C, 67.81; H, 6.82; N, 6.43.
The compounds of Examples 1-3 were tested in the rhino mouse model hereinbefore described at a concentration of 2S 0.1%. All of the compounds improved the appearance of the skin.
SUBSTITUTF SHEET
r r r ' crystallization of the residue from chloroform/hexane, 8.71 g (65%) of methyl 6-aminonicotinate, mp 153-155C; MS: m/e, 152; NMR (CDCl3j consistent with product.
A 500 ml three-neck round-bottom flask equipped with a stirrer and a condenser was charged with 7.67 g (0.049 mole) of methyl 6-aminonicotinate (prepared as described above) and 150 ml of tetrahydrofuran; 6.81 ml (4.96 g; 0.049 mole) of triethylamine and 12.29 g (0.049 mole) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoylchloride(prepared as described in Example 1) were then added and the mixture stirred at room temperature overnight. After evaporation in vacuo, the residue was partitioned between water and ethyl acetate, the organic layer was washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica, using hexane/ethyl acetate as the eluant. The major LP spot wa~ collected to give a tan solid [NMR (CDCl3) consistent with the methyl es~er of the desired product]. This material was dissoived in 50 ml of tetrahydrofuran, 50 ml of 2N NaOH was added and the mixture was stirred at room - temperature overnight. After partial evaporation ln vacuo to remove the organic solvent, the aqueous solution was acidified to pH 4 with 6N HCl to give a cream-colored precipitate, which was filtered and recrystallized from ethanol to afford 6.32 g (37%) of the title compound as white crystals, mp > 240C; MS: m/e, 352; NMR (DMSO-d6) consistent with product. Anal. Calcd. for ~H~N2O3: C, 71.56; H, 6.86; N, 7.95. Found: C, 71.24; H, 7.11; N, 7.87.
6-r3-(1-AdamantYl)-4-methoxv-benzoylamino1-nicotinic acid A 150 mL three-neck round-bottom flask equipped with a stirrer and a condenser was charged with 250 mg (0.0016 mole) of methyl 6-aminonicotinate (prepared as described in Example 3) and 15 mL of tetrahydrofuran; 0.23 mL (0.16 g;
0.0016 mole) of triethylamine and 0.5 g (0.0016 mole) of 3-~1-adamantyl)-4-methoxybenzoyl c~loride (prepared according 5~33~1TlJIE S~?FT
,~
a, ~
~ ~ ~ . . .. . .
~ ~ r ~ ' ' ' to the method of B. Shroot et al., as described in U.S.
Patent No. 4,927,928) were then added and the mixture stirred at room temperature overnight. After evaporation in vacuo, the residue was partitioned between water and ethyl acetate, the organic layer was washed with water and brine, dried over anhydrous and evaporated in vacuo. The residue was purified by column chromatography on silica, using hexane/ethyl acetate as the eluant. The major and less lipophilic spot was collected to give a tan solid tNMR
(CDCl3) consistent with methyl ester of the desired product].
This material was dissolved in 5 mL of tetrahydrofuran, 3 mL
of 2N aqueous NaOH were added and the mixture was stirred at room temperature overnight. After partial evaporation n vacuo to remove the organic solvent, the aqueous solution was acidified to pH 4 with 6N HCl to give a white precipitate, which was filtered and recrystallized from ethanol to afford 203 mg (31%) of the title compound as white crystals, mp >250C; MS: m/e, 406; NMR (DMSO-d6) consistent with product. Anal. Calcd. for C24H26N2O4-H2O: C, 67.91; H, 6.65; N, 6.60. Found: C, 67.81; H, 6.82; N, 6.43.
The compounds of Examples 1-3 were tested in the rhino mouse model hereinbefore described at a concentration of 2S 0.1%. All of the compounds improved the appearance of the skin.
SUBSTITUTF SHEET
Claims (18)
1. A compound of the formula:
or I II
or a pharmaceutically acceptable base salt or a C1 to C8 alkyl-derived ester prodrug thereof, wherein R1 is C1 to C8 alkyl and Q is selected from , , , , and wherein Y is selected from , , , , , , and and Z is selected from groups of the formula , with the pharmaceutically acceptable salt and the alkyl ester prodrug of the formula I or II compound being derived from the aforesaid Y and Z acid groups, said prodrug being a compound wherein Y is selected from , , , , , , and and Z is selected from groups of the formula , wherein R2 is C1 to C8 alkyl, phenyl-C1 to C8 alkyl or substituted phenyl-C1 to C8-alkyl wherein the substituted phenyl may be substituted with one or two substituents selected from C1 to C4 alkyl and halogen.
or I II
or a pharmaceutically acceptable base salt or a C1 to C8 alkyl-derived ester prodrug thereof, wherein R1 is C1 to C8 alkyl and Q is selected from , , , , and wherein Y is selected from , , , , , , and and Z is selected from groups of the formula , with the pharmaceutically acceptable salt and the alkyl ester prodrug of the formula I or II compound being derived from the aforesaid Y and Z acid groups, said prodrug being a compound wherein Y is selected from , , , , , , and and Z is selected from groups of the formula , wherein R2 is C1 to C8 alkyl, phenyl-C1 to C8 alkyl or substituted phenyl-C1 to C8-alkyl wherein the substituted phenyl may be substituted with one or two substituents selected from C1 to C4 alkyl and halogen.
2. A compound according to claim 1, said compound being a free carboxylic acid of the formula I or II.
3. A compound according to claim 1, said compound selected from the group consisting of:
4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoyloxy)-benzoic acid;
4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyloxy-carbonyl)-benzoic acid;
6-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphtho-ylamino)-nicotinic acid; and 6-[3-(1-adamantyl)-4-methoxy-benzoylamino]-nicotinic acid.
4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoyloxy)-benzoic acid;
4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyloxy-carbonyl)-benzoic acid;
6-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphtho-ylamino)-nicotinic acid; and 6-[3-(1-adamantyl)-4-methoxy-benzoylamino]-nicotinic acid.
4. A pharmaceutical composition for treating aging skin, comprising a pharmaceutically acceptable carrier and a dermatologically-effective amount of a compound according to claim 1, 2 or 3.
5. A use of a compound according to claim 1, 2 or 3 in preparing a pharmaceutical composition for treating the disorders of aging skin in an afflicted subject.
6. A pharmaceutical composition useful for treating leukemia, comprising a pharmaceutically acceptable carrier and an anti-leukemically effective amount of a compound according to claim 1, 2 or 3.
7. A composition according to claim 6, adapted to be administered as an oral dosage form.
8. A use of a compound according to claim 1, 2 or 3 in preparing a pharmaceutical composition for treating leukemia.
23a
23a
9. A process for preparing a compound of the formula, or I II
or a pharmaceutically acceptable salt or a C1 to C8 alkyl-derived ester prodrug thereof, wherein R1 is C1 to C8 alkyl and Q is selected from , , , , and wherein Y is selected from , , , , , and and Z is selected from groups of the formula:
, with the pharmaceutically acceptable salt and the said C1 to C8 alkyl ester prodrug of the formula I compound both being derived from the aforesaid Y and Z acid groups, said prodrug being a compound wherein Y is selected from , , , , , , and and Z is selected from groups of the formula , wherein R2 is C1 to C8 alkyl, phenyl-C1 to C8 alkyl or substituted phenyl-C1 to C8 alkyl wherein the substituted phenyl may be substituted with one or two substituents selected from C1 to C4 alkyl and halogen;
(a) characterized in that the amides are prepared by reacting an acid chloride of the formula ClCO-K-CO2R2, wherein K is heteroarylene derived from decarboxylated Y and R2 is C1 to C8 alkyl, phenyl-C1 to C8 alkyl having up to two substituents on the phenyl moiety selected from C1 to C4 alkyl and halogen, with an amine of the formula:
or , wherein R1 is C1 to C8 alkyl, or by reacting an amino acid ester of the formula H2N-K-CO2R2 wherein K is heteroarylene as previously defined and R2 is as defined above with an acid chloride of the formula:
or , wherein R1 is C1 to C8 alkyl, in the presence of a base to yield a prodrug compound of the formulae:
, , a n d , followed by hydrogenolysis of the aforesaid prodrug intermediate compound to yield the corresponding half-acid ester final product of the structural formulae I and II
wherein Q is , , or , wherein Y and Z
are each as defined above; and thereafter, (c) when required, converting a free carboxylic acid final product of structural formula I or II, as originally defined, into a pharmaceutically acceptable base salt of said acid or into a C1 to C8 alkyl-derived ester prodrug of same, as previously defined, by using conventional means.
or a pharmaceutically acceptable salt or a C1 to C8 alkyl-derived ester prodrug thereof, wherein R1 is C1 to C8 alkyl and Q is selected from , , , , and wherein Y is selected from , , , , , and and Z is selected from groups of the formula:
, with the pharmaceutically acceptable salt and the said C1 to C8 alkyl ester prodrug of the formula I compound both being derived from the aforesaid Y and Z acid groups, said prodrug being a compound wherein Y is selected from , , , , , , and and Z is selected from groups of the formula , wherein R2 is C1 to C8 alkyl, phenyl-C1 to C8 alkyl or substituted phenyl-C1 to C8 alkyl wherein the substituted phenyl may be substituted with one or two substituents selected from C1 to C4 alkyl and halogen;
(a) characterized in that the amides are prepared by reacting an acid chloride of the formula ClCO-K-CO2R2, wherein K is heteroarylene derived from decarboxylated Y and R2 is C1 to C8 alkyl, phenyl-C1 to C8 alkyl having up to two substituents on the phenyl moiety selected from C1 to C4 alkyl and halogen, with an amine of the formula:
or , wherein R1 is C1 to C8 alkyl, or by reacting an amino acid ester of the formula H2N-K-CO2R2 wherein K is heteroarylene as previously defined and R2 is as defined above with an acid chloride of the formula:
or , wherein R1 is C1 to C8 alkyl, in the presence of a base to yield a prodrug compound of the formulae:
, , a n d , followed by hydrogenolysis of the aforesaid prodrug intermediate compound to yield the corresponding half-acid ester final product of the structural formulae I and II
wherein Q is , , or , wherein Y and Z
are each as defined above; and thereafter, (c) when required, converting a free carboxylic acid final product of structural formula I or II, as originally defined, into a pharmaceutically acceptable base salt of said acid or into a C1 to C8 alkyl-derived ester prodrug of same, as previously defined, by using conventional means.
10. A process as claimed in parts (a) and (b) of claim 9, characterized by the fact that the acylation reaction is carried out in a reaction-inert organic solvent under substantially anhydrous conditions in the presence of a tertiary amine as the base.
11. A process as claimed in parts (a) and (b) of claim 9, characterized by the fact that the acylation reaction is conducted at a temperature ranging from about -20°C up to about the reflux temperature of the reaction mixture.
12. A process as claimed in claim 10, characterized by the fact that the acylation reaction is carried out in tetrahydrofuran in the presence of triethylamine and at a temperature ranging from about 0°C up to room temperature.
13. A process as claimed in part (a) of claim 9, characterized by the fact that the hydrolysis of the amido ester prodrug intermediate compound to the corresponding amido carboxylic acid final product of structural formulae I and II is effected under alkaline conditions.
14. A process as claimed in part (b) of claim 9, characterized by the fact that the hydrogenolysis of the diester prodrug intermediate compound to the corresponding half-acid ester final product of structural formulae I and II is effected by means of catalytic hydrogenation via a palladium-on-carbon catalyst.
15. The process as claimed in part (a) of claim 9 wherein the compound prepared is 6-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoylamino)-nicotinic acid.
16. The process as claimed in part (a) of claim 9 wherein the compound prepared is 6-[3-(1-adamantyl)-4-methoxybenzoylamino)-nicotinic acid.
17. The process as claimed in part (b) of claim 9, wherein the compound prepared is 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoyloxy)-benzoic acid.
18. The process as claimed in part (b) of claim 9 wherein the compound prepared is 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyloxycarbonyl)-benzoic acid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76457891A | 1991-09-24 | 1991-09-24 | |
| US764,578 | 1991-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2119571A1 true CA2119571A1 (en) | 1993-04-01 |
Family
ID=25071126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002119571A Abandoned CA2119571A1 (en) | 1991-09-24 | 1992-08-10 | Retinoids and their use in treating skin diseases and leukemia |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0642499A1 (en) |
| JP (1) | JPH06507178A (en) |
| CA (1) | CA2119571A1 (en) |
| FI (1) | FI941345A (en) |
| PT (1) | PT100878A (en) |
| WO (1) | WO1993006086A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420145A (en) * | 1993-03-22 | 1995-05-30 | Koichi Shudo | Carboxylic acid derivative |
| US5780676A (en) * | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| US5962731A (en) * | 1992-04-22 | 1999-10-05 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
| PT637297E (en) * | 1992-04-22 | 2001-01-31 | Ligand Pharm Inc | SELECTIVELY COMPOUNDS FOR RETINOID X RECEPTORS |
| CA2137997A1 (en) * | 1994-01-03 | 1995-07-04 | John E. Starrett, Jr. | Retinoid-like compounds |
| US5648385A (en) * | 1994-01-03 | 1997-07-15 | Bristol-Myers Squibb Co. | Retinoid-like compounds |
| US5498755A (en) * | 1994-08-23 | 1996-03-12 | Chandraratna; Roshantha A. | Disubstituted aryl and heteroaryl imines having retinoid-like biological activity |
| US5559248A (en) * | 1995-04-05 | 1996-09-24 | Bristol-Myers Squibb Co. | Retinoid-like heterocycles |
| AU7598596A (en) * | 1995-11-01 | 1997-05-22 | Allergan, Inc. | Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity |
| US5726191A (en) * | 1995-11-16 | 1998-03-10 | Hoffmann-La Roche Inc. | Aromatic carboxylic acid esters |
| AU3958200A (en) * | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2022140467A1 (en) * | 2020-12-21 | 2022-06-30 | Samson Pharma, Llc | Topical compositions and methods of treating skin diseases and conditions with such compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3729568A (en) * | 1969-09-23 | 1973-04-24 | Johnson & Johnson | Acne treatment |
| US4067975A (en) * | 1975-08-04 | 1978-01-10 | Yu Ruey J | Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide |
| NO905543L (en) * | 1989-12-27 | 1991-06-28 | Hoechst Roussel Pharma | PROCEDURE FOR THE PREPARATION AND USE OF AMINOPYRIDINYLMETHANOLS AND AMINOMETHYLPYRIDINAMINES. |
-
1992
- 1992-08-10 EP EP92917698A patent/EP0642499A1/en not_active Withdrawn
- 1992-08-10 JP JP5506024A patent/JPH06507178A/en active Pending
- 1992-08-10 CA CA002119571A patent/CA2119571A1/en not_active Abandoned
- 1992-08-10 WO PCT/US1992/006485 patent/WO1993006086A1/en not_active Application Discontinuation
- 1992-09-18 PT PT100878A patent/PT100878A/en not_active Application Discontinuation
-
1994
- 1994-03-23 FI FI941345A patent/FI941345A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT100878A (en) | 1993-10-29 |
| WO1993006086A1 (en) | 1993-04-01 |
| FI941345A0 (en) | 1994-03-23 |
| JPH06507178A (en) | 1994-08-11 |
| FI941345A (en) | 1994-03-23 |
| EP0642499A1 (en) | 1995-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2163906C2 (en) | Aryl- or heteroarylamides of tetrahydronaphthalene-, chroman-, thiochroman- and 1,2,3,4-tetrahydroquinoline carboxylic acids showing retinoid-like biological activity | |
| RU2191009C2 (en) | METHODS OF THERAPY BY APPLYING THE COMPOUNDS EITHER OF SPECIFIC OR SELECTIVE ACTIVITY TO RETINAL ACID RECEPTOR RARα | |
| DK172070B1 (en) | Benzonaphthalene derivatives, processes for their preparation and use, and their pharmaceutical and cosmetic preparations | |
| JP3197011B2 (en) | Diaromatic compounds and their use in human and veterinary medicine and cosmetics | |
| JP2548176B2 (en) | Benzopyranyl and benzothiopyranylbenzene compounds, process for their preparation, cosmetics and human / animal drugs | |
| EP0920312B1 (en) | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents | |
| US4876381A (en) | Naphthalene derivatives possessing a retinoid-type action, processes for their preparation, and medicinal and cosmetic compositions containing these derivatives | |
| DE69205725T2 (en) | Imino derivatives, processes for their preparation and their use in human and veterinary medicine and in cosmetics. | |
| CA2119571A1 (en) | Retinoids and their use in treating skin diseases and leukemia | |
| HU220240B (en) | Use of retinoids in cosmetic compositions or for the manufacture of pharmaceutical compositions | |
| KR100263581B1 (en) | Pharmaceutical and cosmetic compositions comprising bicyclic-aromatic compounds | |
| JPH06509558A (en) | Novel aromatic polycyclic compounds and their use in human or veterinary medicine and cosmetics | |
| JPH0255430B2 (en) | ||
| FR2601002A1 (en) | AROMATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND IN COSMETICS | |
| JPH09202744A (en) | Biaromatic compound and medicinal and cosmetic composition containing the same and its use | |
| JPS62221681A (en) | Novel benzofuran derivative, manufacture and medicinal and cosmetic composition | |
| JP2634394B2 (en) | Method for producing 5,8,11-eicosatriic acid | |
| JPH08301760A (en) | Skin preparation for external use | |
| JPH11507960A (en) | Bicyclic aromatic compounds, compositions containing them and uses thereof | |
| JP3282630B2 (en) | Benzimidazole derivative compound, its production method and its cosmetic use | |
| KR20040000638A (en) | Kojic acid derivative and preparation method thereof | |
| US5212203A (en) | Aromatic benzamido compounds; their preparation and their use in human or veterinary medicine or in cosmetic preparations | |
| RU2185373C2 (en) | Biaromatic compounds and pharmaceutical and cosmetic compositions based on thereof | |
| DK170558B1 (en) | Naphthyl aromatic compounds, processes for their preparation, pharmaceutical and cosmetic preparations thereof, and use of the compounds for the preparation of pharmaceutical preparations | |
| JP2002518371A (en) | Diaryl selenide compounds and their use in human or animal medicine and cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |